The Experts below are selected from a list of 129 Experts worldwide ranked by ideXlab platform
J Giannios - One of the best experts on this subject based on the ideXlab platform.
-
eradication of metastatic hrbc resistant to trastuzumab and cetuximab after treatment with stealth nanoparticle formulation composed of clamp pna against mrna of sgca1 b1 anti muc1 chimeric mab and Vinorelbine Tartrate
2008Co-Authors: I Athanasiadis, J GianniosAbstract:14640 Background: For HRBC,the unmet medical need is high due to the lack of treatment options.Overexpression of sGC,MUC1and bcl-2 causes immuno-and chemoresistance. Methods: We obtain surgically s...
-
pegylated liposomal anti eif3c shrna Vinorelbine Tartrate formulation sevina v inhibits oncogenic protein translational initiation and oncogene addiction inducing pcd type i ii and iii in nsclc chemoresistant to taxanes
2008Co-Authors: J Giannios, N Alexandropulos, E Michailakis, A KanellopoulosAbstract:19059 Background: eiF3c is required for the initiation of protein translation,and directly interacts with mTOR activating eIF4e,which is overexpressed in NSCLC.mTOR activates the PI3K/AKT signal tr...
-
diabody Vinorelbine conjugate dvc composed of Vinorelbine Tartrate conjugated to anti dnmt1 shh di diabody induce adcc cdc amp and inhibit dna methylation
2007Co-Authors: G N John, J Giannios, E Seraj, G Kanelopulos, P Ginopulos, N AlexandropulosAbstract:11503 Background: Hormone refractory breast cancer (HRBC) is incurable due to malignant stem cells,which represent a potential nidus for the recurrent cancer that arises after treatment failure. Me...
-
ascrit antisense chemoradioimmunotherapy consisting of anti poem arg gly asp scfv linked onto high energy radioisotopes Vinorelbine Tartrate and 21 nucleotide double stranded sirna targeted to dnmt1 induce apoptosis in metastatic breast cancer mbc characterized by hypermethylated p53 p16 rassf1a rar b2 brca2 h1c1 esri1 cdh1 trbeta1 gstp1 ccnd2 and overexpression of bcl 2 cdc25c raf 1 and α8β1 integrin
2005Co-Authors: J Giannios, P Lambrinos, E Maragudakis, N AlexandropoulosAbstract:Metastatic breast cancer (MBC) is resistant to almost all cytotoxic drugs and radiation, making it one of the most aggressive malignancies in humans, with the worst mortality. The failure of tumour cells to undergo apoptosis causes resistance to chemoradiological therapies due to overexpression of oncogenes and transcriptionally repressed apoptotic tumour suppressor genes due to aberrant methylation (CIMP+). Also, upregulation of the ECM gene POEM is associated with adhesion, migration and invasion of highly aggressive and MBC.
Kristin C Oberg - One of the best experts on this subject based on the ideXlab platform.
-
Vinorelbine Tartrate induced pulmonary edema confirmed on rechallenge
1999Co-Authors: Christine E Cattan, Kristin C ObergAbstract:A 67-year-old woman with metastatic breast cancer experienced sudden and profound pulmonary edema within 45 minutes after completion of intravenous administration of Vinorelbine Tartrate on two occasions. Both times the drug was discontinued and the patient was treated aggressively with oxygen, intravenous furosemide, and a vasodilator. The patient suffered no lasting medical complications due to the reaction. Until clear documentation and the mechanism for occurrence of this reaction are known, patients receiving Vinorelbine should be monitored closely, particularly in the first few hours after intravenous administration.
Ingrid Hings - One of the best experts on this subject based on the ideXlab platform.
-
respiratory failure following Vinorelbine Tartrate infusion in a patient with non small cell lung cancer
1997Co-Authors: Chrisostomos Kouroukis, Ingrid HingsAbstract:Vinorelbine Tartrate (Navelbine [Burroughs Wellcome; Research Triangle Park, NC; Pierre Fabre Medicament; Paris, France]) is used in the treatment of non-small cell lung cancer (NSCLC), breast cancer, and some gynecologic malignant neoplasms. The reported prevalence of adverse effects involving the respiratory system is less than 5% and involves mostly dyspnea with occasional interstitial infiltrates. A patient with a hypercoagulable state and diffuse pulmonary NSCLC developed acute respiratory failure soon after Vinorelbine infusion. Physicians should be aware of possible increased pulmonary toxicity of Vinorelbine in patients with diffuse pulmonary NSCLC.
T A Rehmeyer - One of the best experts on this subject based on the ideXlab platform.
-
assessing and managing venous irritation associated with Vinorelbine Tartrate navelbine
1995Co-Authors: C N Rittenberg, R J Gralla, T A RehmeyerAbstract:PURPOSES/OBJECTIVES To determine the effect of duration of infusion time on venous irritation in patients receiving Vinorelbine Tartrate (Navelbine, Burroughs Wellcome Co., Research Triangle Park, NC) in combination with cisplatin or mitomycin. DESIGN Prospective and descriptive. SETTING Five outpatient hematology/oncology units in southern Louisiana and Mississippi. SAMPLE 96 patients receiving Vinorelbine in combination with cisplatin or mitomycin through a peripheral vein. METHOD Nurses completed the Venous Irritation Record (VIR), on which they documented the incidence of irritation reactions on the day of infusion as well as 24 hours and one to two weeks later. MAIN RESEARCH VARIABLES Incidence and severity of venous irritation as well as the duration of administration. FINDINGS Significantly lower incidence of venous irritation at 6-10 minute infusion rate was observed (p < 0.05). No difference in incidence was observed when Vinorelbine was given with a vesicant (mitomycin) or a nonvesicant (cisplatin) drug. CONCLUSIONS Although venous irritation is a problem associated with peripherally administered Vinorelbine, it does not necessitate central line placement. Incidence of this problem can be reduced with a shorter duration of administration. The VIR was feasible, easy to use, and could be adapted for other drugs and other toxicities. The National Cancer Institute Common Toxicity Criteria are not adequate for grading venous irritation reactions. IMPLICATIONS FOR NURSING PRACTICE Vinorelbine should be administered in accordance with the manufacturer's recommendations as a 6-10 minute infusion. Determination of this rate came as a result of clinical nursing research. Nurses involved in clinical trials can and should play a role in describing emergent toxicities and investigating methods to prevent or minimize those toxicities.
Bala Prabhakar - One of the best experts on this subject based on the ideXlab platform.
-
quality by design based development and validation of hplc method for simultaneous estimation of paclitaxel and Vinorelbine Tartrate in dual drug loaded liposomes
2019Co-Authors: Smita Bonde, Chandrakant G Bonde, Bala PrabhakarAbstract:Abstract This paper describes the development of HPLC method for simultaneous estimation of paclitaxel and Vinorelbine Tartrate loaded in dual drug liposomes, using quality by design (QbD) approach. The main objective was to identify the robust chromatographic conditions where an adequate separation of the components with quality peaks, within acceptable run time can be achieved. Based on this objective, Target analytical profile (TAP) was defined and systematic risk analysis was carried out to identify critical method attributes (CMA) having impact on critical quality attributes (CQA). % Organic phase, pH, and ammonium acetate concentration in the aqueous phase were identified as CMA. Box-Behnken design was employed to establish the quantitative relationship between CMA and CQA which was further utilized to generate analytical design space and to develop a control strategy. The effective chromatographic separation was accomplished using C18 (4.6 mm, 100 mm, dp 5 μ) column, and mobile phase consisting of acetonitrile – aqueous phase (30 mM ammonium acetate adjusted to pH 3.2 using ortho phosphoric acid) (55:45, v/v) at ambient temperature and at flow rate of 1 mL/min. The elution was monitored at 249 nm using an ultraviolet detector. This developed HPLC method was validated using ICH guidelines. The method has been successfully used for quality analysis of development batches of dual drug liposomes and stability samples and will be applicable throughout the life cycle of the product.